Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells for Severe/Critical Viral Pneumonia–Related Lung Injury
ChiCTR2400088213Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of mesenchymal stem cells in viral pneumonia, not applicable; "lung injury" is not a specific disease, coronavirus pneumonia and 3 more (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Incidence of disease development events within 28 days. Started Aug 2024; status: recruiting.
02
Drugs
mesenchymal stem cells
03
Conditions
viral pneumonianot applicable; "lung injury" is not a specific diseasecoronavirus pneumoniaAdenovirus Pneumoniainfluenza virus pneumonia
Beyond the preview
Go deeper on ChiCTR2400088213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088213.